Listen to the full audio podcast episode:
Watch other videos from this interview:
DE&I Accountability in Pharma
Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses ways companies can remain accountable for DE&I efforts in pharma in this Pharmaceutical Executive Podcast video.
Across most industries, finding and keeping the right talent is a constant challenge for companies. This challenge is perhaps even more prevalent in the pharmaceutical industry, which requires a significant amount of specialization.
Rebekah Martin, senior VP of reward, inclusion, and talent acquisition for AstraZeneca, discusses recruiting talent in pharma with Meg Rivers, managing editor. Specifically, Martin talks about ways companies can remain accountable for diversity, equity, and inclusion (DE&I) efforts in pharma.
About the speaker
Rebekah Martin is the senior vice president of reward, inclusion, and talent acquisition for AstraZeneca. Martin has a master’s degree in molecular and cellular biochemistry from the University of Oxford and went on to qualify as a lawyer in the UK, joining AstraZeneca in 2011. Since joining, she has held a number of progressively senior roles in the legal team based in the UK and Singapore. She moved to her current role in the HR team in April 2018, where she leads the team responsible for reward strategy, design, and governance at AstraZeneca, talent acquisition, and leads the implementation of AstraZeneca’s global inclusion and diversity strategy. Martin is passionate about breaking down the stigma that can be associated with neurodiversity and believes there is a strong connection between diversity of thought, innovation, and performance.
Recent Videos
Related Content
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
May 15th 2025Article
Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support
May 7th 2025Article
Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Article
Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Article
Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.
